Globe Life (GL)
NYSEFinancialsInsurance - LifeSnapshot 2026-08-31
Reading GL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →NYSEFinancialsInsurance - LifeSnapshot 2026-08-31
Reading GL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Globe Life grows earnings with EPS guidance raised to about $15.65 for 2026. Life insurance net sales rose 6% in Q1, showing steady demand. The company actively buys back shares, repurchasing 1.4 million in Q1. Profit margins remain stable with a low valuation compared to peers.
Recent earnings misses and a guidance cut show risks to growth. Executive stock sales may signal weaker management confidence. The insurance market could face margin pressure and slower sales growth.
The price is about 9% below our fair value near $193, reflecting roughly 8% revenue growth expected by analysts. Our fair value is above the Street median, indicating some upside if growth and margins hold.
Breaks if: EPS guidance falls below $15.40 for FY26
Breaks if: Life and health net sales growth falls below 6% YoY
Share repurchases fall below 1.4 million shares per quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable, long-term thesis with a focus on steady growth and management execution. The current state is mixed, with some positive indicators but also risks related to sector performance and earnings guidance.
The market appears to have priced in a neutral valuation for GL, reflecting a slight expectations gap. The company's premium valuation compared to peers suggests that investors are willing to pay more for its perceived quality, despite recent performance challenges.
Fundamentals are likely to show modest growth, particularly in life and health net sales, which have been on track. However, there is a near-term risk of missing earnings expectations, given the company's recent history and the high miss rate in its industry.
The thesis hinges on the performance of sector bellwethers like MET, AFL, and PRU. If these companies continue to perform well, they could provide a favorable backdrop for GL. Conversely, any negative shifts in their performance could impact GL's momentum.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company announced a new $2.5 billion share buyback. This suggests increased capital returns to shareholders. However, the latest earnings report showed a miss. It also revealed weaker sales trends and softer underwriting margins. These factors may temper expectations for future growth.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: PE ratio rises above 16.55 and stays elevated
Overall, GL's outlook remains cautious, with a focus on management execution and sector trends. Not investment advice.